BioSpace News Archive

AmerisourceBergen was recently named one of America’s “Most Responsible Companies” by Newsweek magazine

At a corporate symposium held in San Diego, Helixmith Co., Ltd. and Genopis, Inc. moved to launch a contract manufacturing business for plasmid DNA production.

The American Academy of Forensic Sciences applauds the release of the National Institute of Justice’s Needs Assessment of Forensic Laboratories and Medical Examiner/Coroner Offices, which was released.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, announced today the preliminary results of its substantial issuer bid (the “Offer”) to repurchase for cancellation up to 4.0 million of its common shares (the “Common Shares”) at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash.

Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced its Chief Executive Officer Bill Athenson will present at Biotech Showcase 2020 to be held January 13-15, 2020 at the Hilton San Francisco Union Square.

Ambu has reached an agreement with Ives EEG Solutions LLC to be the exclusive U.S. distributor of its MRI-compatible single-use electroencephalogram (EEG) cup electrodes.

Diamyd Medical announced today, when all 12 patients have been followed throughout the 30-month period in the open-label trial DIAGNODE-1, that the patients show on average a positive clinical course with a near normal long-term blood sugar and a low need for externally supplied insulin.

SeaStar Medical Foundation receives 501(c)(3) Certificate from the IRS, launches mission to accelerate medical discovery in unmet orphan markets.

Caliburn International, LLC showcased the expanded medical and on-site service delivery options available through its Mobile Medical Unit at recent events at Cape Canaveral Air Force Station, the first of many on-site occupational exams performed by the Caliburn mobile medical team.

iView Therapeutics Inc. today announced that the first patient has been dosed in the Phase 2 IVIEW-1201-01-AIC clinical trial program assessing the efficacy of IVIEW-1201 in patients (age ≥15 years) with Acute Adenoviral Conjunctivitis. First subject was dosed on 19 Dec in India at Disha Eye Hospital Pvt. Ltd. Kolkata under this Phase II Clinical trial program.